10x Insights
Loading account…
Companies / Healthcare / MESA LABORATORIES INC
MLAB

MESA LABORATORIES INC

HealthcareMedical Instruments
Ticker MLABLAKEWOOD, COFiscal year ends MarchBook value per share $32.79Diluted shares 5.8M

Mesa Laboratories, Inc. (Nasdaq: MLAB) is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. The company operates manufacturing facilities in the United States and… From the company’s description.

Fiscal year 2026 · ends 03-31Changes are against fiscal 2025The amber dot is the latest twelve months, to 2026-06-30
Sales & profitability
$249.13M
+3.4% year over year
Last 12 mo $249.72M
7.43%
+0.7 percentage points
Last 12 mo 9.00%
$6.71M
+440.0% year over year
Last 12 mo $4.80M
3.60%
+4.8 percentage points
Last 12 mo 2.54%
Cash & financing
$42.83M
−8.5% year over year
Last 12 mo $55.67M
$39.58M
−7.0% year over year
Last 12 mo $52.87M
0.81
Was 1.11× a year earlier
Last 12 mo 0.76
5.6M
+2.7% year over year
Last 12 mo 5.8M

Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.

What MESA LABORATORIES INC does

In the company’s own words

Mesa Laboratories, Inc. (Nasdaq: MLAB) is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. The company operates manufacturing facilities in the United States and Europe, with sales personnel serving North America, Europe, and the Asia Pacific region, complemented by independent distributors worldwide. Mesa's website is www.mesalabs.com.

The company operates through four reportable segments. The Sterilization and Disinfection Control division manufactures biological, chemical, and cleaning indicators used to assess sterilization and decontamination effectiveness, along with sterility assurance testing services. The Biopharmaceutical Development division develops automated systems for protein analysis and peptide synthesis solutions that accelerate biologic therapy discovery and development. The Calibration Solutions division produces precision measurement and calibration tools for quality control across pharmaceutical, laboratory, and medical device applications, including renal care meters and continuous environmental monitoring systems. The Clinical Genomics division develops high-throughput genetic analysis instruments and consumables using mass spectrometry technology for clinical research applications.

As of March 31, 2026, Mesa employed 717 people, including approximately 450 domestic employees distributed across manufacturing and quality assurance, research and development, sales and marketing, and administrative functions. The company maintains a diversified customer base with no single customer representing more than ten percent of consolidated revenues, though certain divisions exhibit higher customer concentrations. Approximately eight percent of sales derive from Chinese operations, with forty-five percent from other non-U.S. countries, primarily Europe.

Mesa's product portfolio includes recognized brands such as Apex biological indicators, EZTest self-contained indicators, MassARRAY genetic analysis systems, Gyrolab protein analysis instruments, PurePep peptide synthesizers, and DialyGuard, DryCal, DataTrace, and ViewPoint calibration products. The company pursues growth through organic expansion and strategic acquisitions that complement existing portfolios and extend global reach. Mesa's operational philosophy centers on the Mesa Way, a customer-centric lean-based continuous improvement system emphasizing measurement, team empowerment, sustainable improvement, and organizational learning to maximize stakeholder value while advancing its purpose of Protecting the Vulnerable.

Company details
Sector
Healthcare
Industry
Medical Instruments
Headquarters
LAKEWOOD, CO
Fiscal year end
March
CIK
724004
SIC
3823

Financial performance, year by year

Fiscal 2014–2026 · USD
$-304.64M$-153.45M$-2.26M$148.93M$300.12M2014201520162017201820192020202120222023202420252026Last 12 moLast 12 monthsLast 12 months

The full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.

Ownership

Who owns MESA LABORATORIES INC — and what changed

Funds as of 2026Q2 · superinvestors as of 2026-06-30

185
funds hold it
0 of 35
superinvestors hold it
$179.42M
held by funds, at market
32.0%
of shares held by funds

Largest fund holders · MESA LABORATORIES INC’s weight in each

VANGUARD TOTAL STOCK MARKET INDEX FUND
VTI · VANGUARD INDEX FUNDS
0.00%of fund net assets
iShares Russell 2000 ETF
IWM · iShares Trust
0.02%of fund net assets
DIAMOND HILL SMALL CAP FUND
DHSCX · Diamond Hill Funds
3.54%of fund net assets
Column Small Cap Select Fund
CFSSX · Trust for Professional Managers
0.47%of fund net assets
Fidelity Enhanced Small Cap Core ETF
FESM · Fidelity Covington Trust
0.13%of fund net assets

Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.

Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.

Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.

Connected research

Put this business in context.

Compare this company with peers, find it in your funds and follow its financial history with your connected AI:

  • “How do MESA LABORATORIES INC and its peers compare on margins and cash generation over ten years?”
  • “Where did five years of MESA LABORATORIES INC's earnings go — cash, debt, buybacks, reinvestment?”
  • “What changed in MESA LABORATORIES INC's last four quarterly filings that the numbers alone won't show?”
See how it works →All research tools with a subscription. Use your own AI account.